Trial · NCT02682459
ACE-inhibitors in Extracapillary Glomerulonephritis
NCT02682459, Phase 2, Unknown, Monia Lorini
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. ACE-inhibitors in Extracapillary Glomerulonephritis. Trials, record NCT02682459. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02682459
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- ACE-inhibitors in Extracapillary Glomerulonephritis
- NCT number
- NCT02682459
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 22 participants, estimated
- Lead sponsor
- Monia Lorini
- Conditions
- Extracapillary Glomerulonephritis
- Interventions
- Lisinopril
- First posted
- 2016-02-15
- Last updated
- 2018-04-06
- Other registries' IDs
- eudract:2015-003884-12
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | The extent of extracapillary proliferation on light microscopy, measured as % of total glomeruli with proliferative lesions at post-treatment repeat biopsy. | Changes from baseline and 6 and 18 month. | |
| Secondary | Expression of parietal cell proliferation markers at glomerular level, graded on a scale of 0 to 3 (0: no staining, 1: mild, 2: moderate, 3: strong diffuse | Changes from baseline and 6 and 18 month. | |
| Secondary | Number of fibrosclerotic crescents | Changes from baseline and 6 and 18 month. | |
| Secondary | Glomerular Filtration Rate (GFR) measured by iohexol plasma clearance | Changes from baseline and 6, 12 and 18 month. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02682459
GET https://conductscience.org/api/trials/v1/NCT02682459/registered